Výsledky vyhledávání - "A R, Fielder"

Akademický článek

Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trialResearch in context

Autor: Neil Marlow, James D. Reynolds, Domenico Lepore, Alistair R. Fielder, Andreas Stahl, Han Hao, Annemarie Weisberger, Amit Lodha, Brian W. Fleck

Publikováno v: EClinicalMedicine, Vol 71, Iss , Pp 102567- (2024)

Summary: Background: Concerns remain over the long-term safety of vascular endothelial growth factor (VEGF) inhibitors to treat retinopathy of prematurity (ROP). RAINBOW is an open label randomised trial comparing intravitreal ranibizumab (in 0.2 mg

Externí odkaz: https://doaj.org/article/bd57c7c08cf64cf390d072add40bfad0

Zobrazit plný text záznamu

Predicting ROP Severity by Artificial Intelligence: Pragmatic Versus Knowledge-Based Approach

Autor: Graham E. Quinn, Alistair R. Fielder

Publikováno v: Pediatrics

BACKGROUND AND OBJECTIVES: Retinopathy of prematurity (ROP) is a leading cause of childhood blindness. Screening and treatment reduces this risk, but requires multiple examinations of babies, most of whom will not develop severe disease. Previous wor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73a4d212a6baf8b028a9b6501044ce0f
https://doi.org/10.1542/peds.2021-053255

Zobrazit plný text záznamu

Time Course of Retinopathy of Prematurity Regression and Reactivation After Treatment with Ranibizumab or Laser in the RAINBOW Trial

Autor: Brian W. Fleck, James D. Reynolds, Qi Zhu, Domenico Lepore, Neil Marlow, Andreas Stahl, Jun Li, Annemarie Weisberger, Alistair R. Fielder

Publikováno v: Ophthalmology. Retina. 6(7)

To study the time course of retinopathy of prematurity (ROP) regression and reactivation after treatment with intravitreal ranibizumab or laser in the ranibizumab compared with laser therapy for the treatment of infants born prematurely with ROP tria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f2e12d8d2409bc77f3cde6e2b01d55b
https://pubmed.ncbi.nlm.nih.gov/35202890

Zobrazit plný text záznamu

2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial

Autor: Daniel P. Stiehl, Neil Marlow, Domenico Lepore, Brian W Fleck, Andreas Stahl, James D. Reynolds, Alistair R. Fielder, Qi Zhu, Annemarie Weisberger

Publikováno v: The Lancet. Childadolescent health. 5(10)

Intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors is increasingly used to treat retinopathy of prematurity (ROP) in the absence of evidence about long-term efficacy or safety. In this prespecified interim analysis of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3287bc176cafe63bba0dc209c11c18c6
https://pubmed.ncbi.nlm.nih.gov/34391532

Zobrazit plný text záznamu

Delay in presentation to hospital for childhood cataract surgery in India

Autor: Ramesh Kekunnaya, Sethu Sheeladevi, Rahul Ali, John G Lawrenson, Catherine M. Suttle, Alistair R. Fielder, Rishi R Borah

Publikováno v: Eye

Purpose\ud Cataract is one of the major causes of avoidable visual disability in children and the aim of this study was to investigate the age at which children with cataract present for surgery at tertiary hospitals across India.\ud \ud Methods:\ud

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcaca08f51eb123b5e12b3fc304af57e
http://europepmc.org/articles/PMC6292888

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání